-
Mashup Score: 6
Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug discovery that is both first-in-class and best-in-class.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 3Cmbio Launches to Provide a Centralized Hub for Microbiome and Metabolomics Services - 10 hour(s) ago
The new business combines solutions from four companies and will target customers in pharma and biotech, consumer markets, and academia.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet-
Cmbio Launches to Provide a Centralized Hub for Microbiome and Metabolomics Services The new business combines solutions from four companies and will target customers in pharma and biotech, consumer markets, and academia. https://t.co/zpVRlOUpDL
-
-
Mashup Score: 4
Researchers suggest broadly reactive antibodies identified are likely to represent a common mechanism of acquired immunity to severe malaria.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet-
Human Antibody Discovery May Point to Vaccines Protecting Against Severe Malaria Researchers suggest broadly reactive antibodies identified are likely to represent a common mechanism of acquired immunity to severe malaria. https://t.co/wHaGrZRYt4
-
-
Mashup Score: 9Novartis Buys Kate Therapeutics, Expanding in Neuro Gene Therapy - 14 hour(s) ago
Novartis has acquired Kate Therapeutics for up to $1.1 billion, the companies said today, in a deal that expands the buyer’s presence in both neuroscience drug development and gene therapy.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet-
Novartis Buys Kate Therapeutics, Expanding in Neuro Gene Therapy Novartis has acquired Kate Therapeutics for up to $1.1 billion, the companies said today, in a deal that expands the buyer’s presence in both neuroscience drug development and gene therapy. https://t.co/3jvIIY76Fx
-
-
Mashup Score: 1Online Event - 15 hour(s) ago
Like traditional biologics, cell and gene therapies (CGTs) must meet safety and efficacy standards before they can be administered to human patients. But the manufacturing processes used for this new therapy modality are markedly different from those used to make traditional biologics like monoclonal antibodies. And that raises important questions about the appropriate quality control and GMP release testing procedures for these products. Furthermore, because cell and gene therapies are often first-in-clas
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet-
LAST CHANCE! TODAY, our speakers will present important considerations for quality control testing for biosafety and product characterization in GMP release and stability studies of novel cell and gene therapies. REGISTER: https://t.co/L5eKHvyItt @WuXi_AppTec #mRNA https://t.co/nBqoDd5k9c
-
-
Mashup Score: 7Spatial and Single-Cell Data Combined to Create Comprehensive Cell Map of the Human Gut - 16 hour(s) ago
By understanding more about the cycle of inflammation, it might be possible to find new ways to prevent or treat this in IBD.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet-
.@sangerinstitute and collaborators combined spatial and single-cell data from 1.6 million cells to create the most comprehensive cell map of the human gut to date. Mapping these cells can provide further insights into what happens in bowel cancer and IBD. https://t.co/xQlWMKw5yg
-
-
Mashup Score: 15Online Event - 21 hour(s) ago
Biopharma companies face unique challenges in scaling AI-and those challenges vary greatly depending on whether you’re at a small or large biopharma. While large biopharma is pushing ahead with nearly 3x the rate of AI adoption of smaller companies (73% vs. 26%), gaps in AI readiness are evident across both segments, according to the upcoming State of Tech in Biopharma report. Just 14% of large biopharma and 3% of small biopharma report being fully prepared for AI across the critical dimensions of
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet-
NEW WEBINAR! On 12/4, experts from AbbVie and Benchling will share insights into the current tech landscape, AI readiness, and the strategies for digital transformation shaping large and small biopharma. REGISTER: https://t.co/z3mE5ZaxrT @benchling #AI #DrugDiscovery https://t.co/2iY1wwd0uo
-
-
Mashup Score: 7
SSPC and NIBRT will use hybrid modeling techniques to improve process development for advanced therapies under new collaboration.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet-
Ireland’s SSPC and NIBRT Team to Take on Biopharma Bottlenecks SSPC and NIBRT will use hybrid modeling techniques to improve process development for advanced therapies under new collaboration. https://t.co/z0hc57IhKj
-
-
Mashup Score: 8Are Single Cells Capable of a Simple Form of Learning? - 1 day(s) ago
Researchers suggest “one daring idea” would be to apply the concept of habituation to the relationship between cancer and immunity.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet-
.@CRGenomica and @harvardmed uncovered single cells appear capable of a simple form of learning known as habituation. The researchers suggests "one daring idea" would be to apply the concept of habituation to the relationship between cancer and immunity. https://t.co/grHiliF238
-
-
Mashup Score: 6
Abzena’s goal is to help customers optimize drug development strategies, secure funding, and navigate regulatory pathways more effectively.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet-
.@AbzenaGroup Expands Analytical Capabilities to Include GMP Cell-Based Potency Testing Abzena's goal is to help customers optimize drug development strategies, secure funding, and navigate regulatory pathways more effectively. https://t.co/3ZDWH7UwpO
-
Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug discovery that is both first-in-class and best-in-class. https://t.co/giNtsiAwnY